PharmaTelevision - Sunshine Heart: Elaine Stead. 'Offering a brighter future for heart failure patients'

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Sunshine Heart: Elaine Stead. 'Offering a brighter future for heart failure patients'

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Elaine Stead, Vice President Corporate Development of Sunshine Heart.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Sunshine Heart's technology and specialisation

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at AusBiotech's convention in Adelaide. On this show I have Elaine Stead, who is Vice President of Corporate Development at a company called Sunshine Heart , welcome.

Elaine Stead:

Thank you. Thanks for having me.

Fintan Walton:

Pleasure and Elaine, first of all could you just tell us a little bit about the history of Sunshine Heart ? Where the technology comes from and where you are specialized?

Elaine Stead:

Sure, so Sunshine Heart was originally incorporated in Australia, but it was based around a technology originally devised by William Peters, who is a cardiac surgeon who is based in New Zealand, and in 2004 the company was listed on the ASX and we did some initial clinical trials in Australia with some Australian patients which were quite promising and as the technology developed the company has slowly transitioned to Minneapolis where it's now based, because that is the centre of the cardiovascular medical device universe.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Elaine Stead

Vice President

At the time of recording this PTV interview Elaine Stead serves as Vice President Corporate Development of Sunshine Heart Inc. Her previous positions include Investment Manager at CM Capital Investments, Deputy Director at ARI Pty Ltd, Commercial Development Manager at ARI Pty Ltd and CEO at Reproductive Health Science Pty Ltd. Elaine has worked closely with several early stage companies and technologies predominantly in technology identification & packaging, intellectual property protection, and transaction negotiation. Elaine has also played key roles in the formation, fund raising, and management of several start-up companies and has led the negotiations on numerous licensing and research collaboration deals. Elaine has a first class honours degree in biochemistry and a PhD in stem cell biology from the University of Adelaide. She is also a member of AusBiotech.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Sunshine Heart Inc

Sunshine Heart Inc an early stage medical device company, focuses on developing, manufacturing, and commercializing C-Pulse Heart Assist System, for treatment of Class III and ambulatory Class IV heart failure . Product The C-Pulse Heart Assist System utilizes the scientific principles of intra-aortic balloon counter-pulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. The company has developed tools to allow the C-Pulse to be implanted via a small pacemaker-like incision between the patient's ribs and sternum rather than a full sternotomy, and completed its first implant using this less invasive procedure in 2010. Once implanted, the C-Pulse cuff is positioned on the outside of the patient's ascending aorta above the aortic valve. This device does not directly contact the patient's blood and it may be turned on or off at any time allowing the patient intervals of freedom to perform certain activities. The company seeks CE Mark for the C-Pulse. Competition The company's medical device competitors are Thoratec Corporation, HeartWare International Inc, CircuLite, Inc, AbioMed, Inc, Jarvik Heart, Inc, MicroMed Technology, Inc, SynCardia Systems, Inc, Terumo Heart, Inc and World Heart Corporation in the U.S. and Europe; and Berlin Heart GmbH in Europe. History Sunshine Heart Inc was founded in 1999.